MIM
SRNE

MetLife Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

MetLife Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-242,594
Closed -$215K – 2849
2022
Q4 		$215K Buy
242,594
+43,714
+22% +$58K ﹤0.01% 2205
2022
Q3 		$312K Hold
198,880
– – ﹤0.01% 1990
2022
Q2 		$400K Buy
198,880
+80,929
+69% +$140K ﹤0.01% 1818
2022
Q1 		$275K Buy
117,951
+13,416
+13% +$41.8K ﹤0.01% 2148
2021
Q4 		$486K Buy
104,535
+16,362
+19% +$102K ﹤0.01% 1518
2021
Q3 		$673K Sell
88,173
-10,163
-10% -$86.2K 0.01% 1357
2021
Q2 		$953K Buy
98,336
+15,247
+18% +$121K 0.01% 1182
2021
Q1 		$687K Sell
83,089
-19,280
-19% -$204K 0.01% 1342
2020
Q4 		$699K Buy
102,369
+8,421
+9% +$67.6K 0.01% 1302
2020
Q3 		$1.05M Buy
93,948
+14,675
+19% +$134K 0.01% 1009
2020
Q2 		$498K Buy
79,273
+15,945
+25% +$61K 0.01% 1382
2020
Q1 		$117K Buy
63,328
+25,448
+67% +$73.3K ﹤0.01% 1992
2019
Q4 		$128K Sell
37,880
-26,743
-41% -$63.8K ﹤0.01% 2202
2019
Q3 		$138K Buy
64,623
+5,820
+10% +$13.6K ﹤0.01% 2150
2019
Q2 		$157K Buy
58,803
+16,024
+37% +$57.7K ﹤0.01% 2167
2019
Q1 		$203K Hold
42,779
– – ﹤0.01% 1976
2018
Q4 		$103K Hold
42,779
– – ﹤0.01% 2290
2018
Q3 		$188K Hold
42,779
– – ﹤0.01% 2122
2018
Q2 		$308K Buy
+42,779
New +$291K ﹤0.01% 1708

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

MetLife Investment Management's SRNE Position: Q1 2023 in Review

MetLife Investment Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 242,594 shares — an estimated $215K sold.

MetLife Investment Management first reported a position in SRNE in Q2 2018 and held it in 19 quarters. The position peaked at $1.05M in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • MetLife Investment Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • MetLife Investment Management sold 242,594 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $215K.
  • MetLife Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2018 and held it in 19 quarters.
  • MetLife Investment Management's Sorrento Therapeutics, Inc. position peaked at $1.05M in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on MetLife Investment Management's 13F filing for Q1 2023, filed 15 May 2023.